Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMPL Impel Pharmaceuticals		$0.27	$0.02 ▼ $4.20	$956K	1.17	682,655 shs	720,000 shs
LUMO Lumos Pharma	$2.68 +3.5%	$2.85	$2.41 ▼ $4.55	$21.02M	0.65	10,444 shs	4,650 shs
MBRX Moleculin Biotech	$4.30 -7.5%	$6.93	$4.28 ▼ $15.75	$9.59M	1.96	30,390 shs	16,715 shs
STSA Satsuma Pharmaceuticals	$1.10 -0.9%	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	1.83 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMPL Impel Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-97.80%
LUMO Lumos Pharma	+3.47%	+9.39%	-3.60%	-6.62%	-16.36%
MBRX Moleculin Biotech	-7.53%	-3.59%	-24.62%	-37.22%	-63.39%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+5.77%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMPL Impel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	1.4813 of 5 stars	3.5	1.0	0.0	0.0	0.0	2.5	1.3
MBRX Moleculin Biotech	2.1532 of 5 stars	3.5	3.0	0.0	0.0	2.4	0.0	1.3
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMPL Impel Pharmaceuticals	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	3.00	Buy	$18.00	571.64% Upside
MBRX Moleculin Biotech	3.00	Buy	$35.00	713.95% Upside
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MBRX, STSA, IMPL, and LUMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	MBRX Moleculin Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/26/2024	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $20.00
3/20/2024	LUMO Lumos Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMPL Impel Pharmaceuticals	$20.99M	0.00	N/A	N/A	($1.86) per share	0.00
LUMO Lumos Pharma	$2.05M	10.62	N/A	N/A	$3.45 per share	0.78
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMPL Impel Pharmaceuticals	-$106.31M	-$3.13	N/A	N/A	N/A	-353.93%	N/A	-127.43%	N/A
LUMO Lumos Pharma	-$34.03M	-$4.19	N/A	N/A	N/A	-1,659.39%	-85.63%	-65.30%	5/1/2024 (Estimated)
MBRX Moleculin Biotech	-$29.77M	-$13.64	N/A	N/A	N/A	N/A	-80.91%	-67.69%	5/9/2024 (Estimated)
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A

Latest MBRX, STSA, IMPL, and LUMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	LUMO Lumos Pharma	-$1.18	-$1.17	+$0.01	-$1.17	$0.01 million	$0.83 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMPL Impel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMPL Impel Pharmaceuticals	N/A	0.19	0.13
LUMO Lumos Pharma	N/A	5.69	5.69
MBRX Moleculin Biotech	N/A	3.86	3.86
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44

Ownership

Institutional Ownership

Company	Institutional Ownership
IMPL Impel Pharmaceuticals	73.88%
LUMO Lumos Pharma	33.99%
MBRX Moleculin Biotech	15.52%
STSA Satsuma Pharmaceuticals	93.26%

Insider Ownership

Company	Insider Ownership
IMPL Impel Pharmaceuticals	6.20%
LUMO Lumos Pharma	25.40%
MBRX Moleculin Biotech	6.70%
STSA Satsuma Pharmaceuticals	31.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
IMPL Impel Pharmaceuticals	160	23.90 million	22.42 million	Not Optionable
LUMO Lumos Pharma	33	8.12 million	6.06 million	Not Optionable
MBRX Moleculin Biotech	18	2.23 million	2.08 million	Not Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable

MBRX, STSA, IMPL, and LUMO Headlines

Source	Headline
	With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray fiercepharma.com - January 18 at 8:54 PM
	Satsuma City High School usnews.com - August 30 at 5:25 PM
	Japanese pharma acquires its crash-strapped Durham spin-out bizjournals.com - June 9 at 3:18 PM
	Japanese pharma acquires its Durham spin-out bizjournals.com - June 8 at 4:49 PM
	Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine finance.yahoo.com - May 18 at 8:06 PM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA marketwatch.com - May 3 at 5:56 PM
	Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon benzinga.com - May 1 at 8:34 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA marketwatch.com - April 25 at 4:05 PM
	STSA Satsuma Pharmaceuticals, Inc. seekingalpha.com - April 22 at 6:34 PM
	Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting finance.yahoo.com - April 21 at 10:22 AM
	After Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upside msn.com - April 19 at 12:39 AM
	Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA marketwatch.com - April 18 at 1:38 AM
	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyout benzinga.com - April 17 at 3:37 PM
	Peninsula company bets big part of potential $221M sale on future of migraine drug bizjournals.com - April 17 at 3:37 PM
	STSA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Satsuma Pharmaceuticals, Inc. Is Fair to Shareholders markets.buffalonews.com - April 17 at 10:36 AM
	Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical markets.businessinsider.com - April 17 at 10:36 AM
	Satsuma Skyrockets after Acquisition by Shin Nippon msn.com - April 17 at 10:36 AM
	Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today? investorplace.com - April 17 at 9:09 AM
	SNBL to Acquire Satsuma Pharmaceuticals finance.yahoo.com - April 16 at 11:18 PM
	H.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA) markets.businessinsider.com - March 30 at 10:15 AM
	We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Rate finance.yahoo.com - March 30 at 10:15 AM
	Migraine drug maker seeks FDA approval and a partner as it cuts jobs bizjournals.com - March 29 at 1:49 PM
	Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights finance.yahoo.com - March 28 at 6:05 PM
	8-K: Satsuma Pharmaceuticals, Inc. marketwatch.com - February 18 at 2:42 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
PVH Stock Gets 25% Discount: Is Now the Time to Buy?
April 2, 2024 11:25 AM
View PVH Stock Gets 25% Discount: Is Now the Time to Buy?
Delta Airline’s Put Option Activity Isn’t Bad News
March 28, 2024 8:55 AM
View Delta Airline’s Put Option Activity Isn’t Bad News
It’s Time to Buy Into the Super Micro Computer Stock Implosion
April 22, 2024 12:33 PM
View It’s Time to Buy Into the Super Micro Computer Stock Implosion
3 High Short Interest Stocks Ready to Squeeze
April 9, 2024 7:04 AM
View 3 High Short Interest Stocks Ready to Squeeze

All Headlines

Company Descriptions

Impel Pharmaceuticals

NASDAQ:IMPL

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Lumos Pharma

NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Moleculin Biotech

NASDAQ:MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Satsuma Pharmaceuticals

NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial